Introduction to COVID-19

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease was first identified in December 2019 in Wuhan, China. The time from exposure to onset of symptoms is typically around five days but may range from two to fourteen days. Common symptoms are similar to seasonal flu. While the majority of cases result in mild symptoms, some progress to viral pneumonia and multi-organ failure.

Since there is no vaccine or specific antiviral treatment for COVID-19, diagnostic testing is playing a crucial role in the prevention and control of the disease.

COVID-19 testing options

Two kinds of tests are available for COVID-19: serologic test and molecular test.

The serologic test

The serologic test detects antibodies against the virus in serum samples.

The presence of antibodies indicates exposure to the virus and the body’s response to infections. Although antibodies that result from SARS-CoV-2 infection may provide some immunity, the level, and duration of immunity are not yet known.

SBC has developed two types of antibody tests for SARS-CoV-2 — lateral flow immunoassays and enzyme-linked immunosorbent assay (ELISA).

The molecular test

The molecular test detects genetic material of the virus in respiratory specimens (such as nasopharyngeal or oropharyngeal swabs).
Real-time reverse transcription polymerase chain reaction (rRT-PCR) is the gold standard to diagnose COVID-19.

The primers and probe of the SBC SARS-CoV-2 qPCR kit are designed to detect the ORF1ab gene and N gene.
This CE marked test has also received the Taiwan Food and Drug Administration (TFDA) Emergency Use Authorization (EUA).

Serology Testing


Qualitative assessment of IgG

The SBC COVID-19 IgG ELISA Kit is an Enzyme-Linked Immunosorbent Assay (ELISA) intended for qualitative detection of IgG antibodies to SARS-CoV-2 in human serum.

* High sensitivity and specificity

97.1% positive percent agreement (95% CI, 85.5%-99.5%)
Estimated by testing 35 serum samples from patients that were confirmed positive for SARS-CoV-2 by US FDA authorized PCR 15-40 days prior to serum collection.

100% negative percent agreement (95% CI, 95.8%-100%)
Estimated by testing 87 serum samples collected in the US prior to December 2019.

* Full-length spike protein coated microplates (S1 and S2).

* Microplate in strip format (adjustable to sample size)

* Compatible with various open platform ELISA analyzers

* For Research use only

Molecular Testing

  • Spin column
  • One-step (under development)
  • Automated magnetic bead-based
  • Internal control included
  • High sensitivity & specificity
  • POCT (cPCR)
  • Lab-based testing (Mini qPCR)


Ready to use
reagents for qPCR


Gene targets: ORF1ab and N
(Primer and probe design based on the sequence published by China CDC)
RNase P as internal control to prevent false negatives

Performance characteristics

100% match to sequences of SARS-CoV-2 isolates.
No cross reactivity with common respiratory flora and other viral pathogens.
The LoD was determined to be 10 copies/reaction (0.4 copies/µl) for both ORF1ab and N gene.


1.5h-2hrs to obtain result (after extraction)

Our Products

Contact Us

If you are interested in our products, please fill out the form and we'll get back to you shortly

Schweitzer Biotech Company Ltd.
4F, No.18, Ln.120, Sec.1, Neihu Rd., Neihu Dist.,
Taipei City 11493, TAIWAN
+886 (2) 2657 7773

If you see this Google Maps wasn't properly loaded. Please refresh your page 🙂